Rocket Pharmaceuticals Inc. Common Stock (RCKT)

FairStock Score: 58/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earning power and a margin of safety. Rocket Pharmaceuticals does not yet fit that mold. In its filed figures, revenue is not reported, and it has not earned a profit in each of the last four years. The Lynch category computed by FairStock is none, precisely because of losses in each of the last four years. Fiscal 2023 produced a net loss of $245.6 million, fiscal 2024 a net loss of $258.7 million, and fiscal 2025 a net loss of $223.1 million. The fiscal Q2 2026 quarter ended 2026-06-30 did show net income of $123.2 million and diluted EPS of $1.08, but fiscal Q1 2026, ended 2026-03-31, had a net loss of $47.6 million. One positive quarter does not create a proven earnings stream. The balance sheet has low debt, with D/E of 0.07, which helps. But trailing free cash flow is -$170.4 million, and the FCF yield is -67.5% against a $252.5 million market cap at the 2026-10-13 close. That is heavy cash consumption. FairStock's Piotroski F-Score is 2/9 and Altman Z-Score is -0.99, both signs of financial fragility. The P/B of 0.68 and $2.30 price versus a 52-week range of $2.26 to $5.45 may look statistically cheap, but book value in a pre-revenue biotech is not the same as earning power. The business has no commercial moat yet; its value depends on clinical and regulatory success in rare genetic therapies. If the science works, today's price could prove pessimistic. If cash burn continues without revenue, equity holders bear substantial risk. I see a speculative pipeline option, not a Graham-style bargain.

In plain English: Rocket Pharmaceuticals is a late-stage biotech company trying to develop genetic medicines for rare diseases. It currently reports no revenue and has lost money in each of the last four years, though one recent quarter showed a profit. At $2.30 on 2026-10-13, the stock trades below its accounting value per share, but because the company is still unprofitable and burning cash, the price looks speculative rather than clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer